within Pharmacolibrary.Drugs.ATC.L;

model L03AB13
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.82,
    Cl             = 0.15 / 1000 / 60,
    adminDuration  = 600,
    adminMass      = 125 / 1000000,
    adminCount     = 1,
    Vd             = 0.0047,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.016666666666666666,
    Tlag           = 600
  );

  annotation(Documentation(
    info ="<html><body><p>Peginterferon beta-1a is a pegylated form of interferon beta-1a approved for the treatment of relapsing forms of multiple sclerosis (MS). The PEGylation increases the half-life, allowing for less frequent dosing compared to conventional interferon beta-1a preparations. It is currently approved and in clinical use.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters are reported for adult patients with relapsing-remitting MS. Most data are from healthy subjects and MS patients administered a subcutaneous dose of 125 micrograms every 2 weeks.</p><h4>References</h4><ol><li><p>Zhao, Y, et al., &amp; Butts, CL (2022). Pharmacokinetics/pharmacodynamics by race: Analysis of a peginterferon β-1a phase 1 study. <i>Med (New York, N.Y.)</i> 3(9) 612–621.e3. DOI:<a href=&quot;https://doi.org/10.1016/j.medj.2022.06.006&quot;>10.1016/j.medj.2022.06.006</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/35853458/&quot;>https://pubmed.ncbi.nlm.nih.gov/35853458</a></p></li><li><p>Simó, M, &amp; Iljicsov, A (2017). [Role of peginterferon-β-1a in the therapy of multiplex sclerosis]. <i>Ideggyogyaszati szemle</i> 70(11-12) 365–368. DOI:<a href=&quot;https://doi.org/10.18071/isz.70.0365&quot;>10.18071/isz.70.0365</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/29870644/&quot;>https://pubmed.ncbi.nlm.nih.gov/29870644</a></p></li><li><p>Hu, X, et al., &amp; Hung, S (2015). Pharmacokinetics, pharmacodynamics, and safety of peginterferon beta-1a in subjects with normal or impaired renal function. <i>Journal of clinical pharmacology</i> 55(2) 179–188. DOI:<a href=&quot;https://doi.org/10.1002/jcph.390&quot;>10.1002/jcph.390</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/25187030/&quot;>https://pubmed.ncbi.nlm.nih.gov/25187030</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end L03AB13;
